Cardinal Health has completed the sale of its Pharmaceutical Technologies and Services (PTS) segment to The Blackstone Group for approximately $3.3 billion. Cardinal Health announced in November of last year that it planned to divest PTS to focus resources on its four remaining segments serving healthcare provider customers. “We are pleased to begin this new chapter in our history,” said John Lowry, chief executive officer of PTS. “We have a long heritage of providing custome...